Kunihiro Iwamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kunihiro Iwamoto has a total of 291 co-authors. Here are the top co-authors by number of shared publications:
- Norio Ozaki
Department of Psychiatry, Nagoya University Graduate School of Medicine, Aichi, Japan
45 shared publications Norio Ozaki
19 shared publications- Seiko Miyata
Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan
16 shared publications Akiko Noda
Department of Biomedical Sciences, Chubu University Graduate School of Life and Health Sciences, 1200, Matsumoto-cho, Kasugai-shi, Aichi, 487-8501, Kasugai, Japan
13 shared publicationsMasahiko Ando
Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan
13 shared publicationsNaoko Kawano
Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
13 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Wiley in Psychogeriatrics
- Vol. 26 (6)
Clinical Trajectory of Late‐Onset Delusional Disorder Toward Evolving Dementia With Lewy Bodies
Recent clinical observations indicate that late‐onset psychosis can precede the onset of dementia with Lewy bodies (DLB). However, its longitudinal clinical trajectory remains poorly understood. Delusional disorder (DD) in older adults is relatively uncommon and poor insight frequently leads to refusal of psychiatric care, limiting available data despite its long‐standing diagnostic recognition. This article focuses on late‐onset DD in relation to subsequent development of DLB. We revisited our previously reported cases in which delusions were the initial manifestation of Lewy body disease (LBD) and aimed to identify the shared clinical features to help delineate more homogeneous subgroups within the heterogeneous spectrum of late‐onset psychosis. These cases with late‐onset DD revealed a recurring phenotype characterised by onset in the 50s and 60s, reluctance to seek psychiatric care, eventual hospitalisation, poor antipsychotic tolerance and delayed emergence of dementia accompanied by core features of DLB. Clinicopathological examination of four cases raises the hypothesis that persistent delusions may emerge in the presence of relatively restricted Lewy pathology, preceding the development of widespread cortical involvement and overt dementia. Relative preservation of neuronal populations in the substantia nigra may account for the absence of parkinsonism during the early phases dominated by isolated delusions. Despite long‐standing delusions beginning in the 50s and 60s, a common age range for DLB onset (mid‐70s and older) was observed, indicating an exceptionally prolonged prodromal period. These findings suggest that late‐onset DD associated with LBD may follow a clinical trajectory distinct from that of mild cognitive impairment with Lewy bodies (MCI‐LB), the most common clinical phenotype of prodromal DLB. Differentiating DD from broader late‐onset psychosis categories may facilitate future research by reducing heterogeneity and stratifying cases with potentially prolonged periods without dementia or parkinsonism. Clinical and pathological reports of late‐onset DD remain scarce and further case documentation is warranted.
- 4 November 2026
- Published by Wiley in Psychogeriatrics
- Vol. 26 (6)
Open AccessClinical Trajectory of Late‐Onset Delusional Disorder Toward Evolving Dementia With Lewy Bodies
Recent clinical observations indicate that late‐onset psychosis can precede the onset of dementia with Lewy bodies (DLB). However, its longitudinal clinical trajectory remains poorly understood. Delusional disorder (DD) in older adults is relatively uncommon and poor insight frequently leads to refusal of psychiatric care, limiting available data despite its long‐standing diagnostic recognition. This article focuses on late‐onset DD in relation to subsequent development of DLB. We revisited our previously reported cases in which delusions were the initial manifestation of Lewy body disease (LBD) and aimed to identify the shared clinical features to help delineate more homogeneous subgroups within the heterogeneous spectrum of late‐onset psychosis. These cases with late‐onset DD revealed a recurring phenotype characterised by onset in the 50s and 60s, reluctance to seek psychiatric care, eventual hospitalisation, poor antipsychotic tolerance and delayed emergence of dementia accompanied by core features of DLB. Clinicopathological examination of four cases raises the hypothesis that persistent delusions may emerge in the presence of relatively restricted Lewy pathology, preceding the development of widespread cortical involvement and overt dementia. Relative preservation of neuronal populations in the substantia nigra may account for the absence of parkinsonism during the early phases dominated by isolated delusions. Despite long‐standing delusions beginning in the 50s and 60s, a common age range for DLB onset (mid‐70s and older) was observed, indicating an exceptionally prolonged prodromal period. These findings suggest that late‐onset DD associated with LBD may follow a clinical trajectory distinct from that of mild cognitive impairment with Lewy bodies (MCI‐LB), the most common clinical phenotype of prodromal DLB. Differentiating DD from broader late‐onset psychosis categories may facilitate future research by reducing heterogeneity and stratifying cases with potentially prolonged periods without dementia or parkinsonism. Clinical and pathological reports of late‐onset DD remain scarce and further case documentation is warranted.
- Open Access
- 20 April 2026
- Published by Wiley in Psychiatry and Clinical Neurosciences Reports
- Vol. 5 (2) , e70337
ADHD medications and drug withdrawal: A pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database
- 20 April 2026
- Published by Wiley in Psychiatry and Clinical Neurosciences Reports
- Vol. 5 (2) , e70337
Open AccessADHD medications and drug withdrawal: A pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database
- Open Access
- 11 February 2026
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 46 (1) , e70092
Evaluating and Determining the Effects of Psychotropic Drugs on Motor Vehicle Driving Performance: Key Considerations of the Japanese Guideline and Criteria for Clinical Implementation of Evidence
The cross‐national differences in automobile driving precautions stated in psychotropic drug package inserts primarily reflect regulatory policies and insufficient evaluation method standardization until recent years, rather than intrinsic ethnic differences. In January 2025, the Ministry of Health, Labour and Welfare (MHLW) of Japan issued the Criteria for Determining the Effects of Psychotropic Drugs on Motor Vehicle Driving Performance. These criteria were published as an appendix to an earlier guideline for evaluating these effects published in December 2022. These guidelines and criteria, developed by the authors, provide methods for evaluating the effects of psychotropic drugs. However, these are not intended to assess the fitness of an individual patient to drive. The MHLW guideline and criteria recommend a tiered approach for assessing clinically meaningful driving impairment. Adverse events affecting alertness, such as drowsiness, caused by psychotropic drugs on driving performance are more frequent during the initial treatment stages and dose escalation. Therefore, evaluating the effects of psychotropic drugs on driving performance requires careful consideration of the persistence of clinically meaningful impairment. Additionally, understanding the magnitude and duration of such effects is crucial for selecting appropriate treatments and offering effective guidance to patients. The MHLW criteria categorize the effects of psychotropic drugs on driving performance into four levels based on their magnitude and duration. Furthermore, the MHLW criteria could help to determine which clinical trials are necessary to evaluate the persistence of clinically meaningful impairment. Namely, the MHLW criteria could be used to structure the substantial evidence needed for evaluating the effects on driving performance for approval applications and clinical implementation.
- 11 February 2026
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 46 (1) , e70092
Open AccessEvaluating and Determining the Effects of Psychotropic Drugs on Motor Vehicle Driving Performance: Key Considerations of the Japanese Guideline and Criteria for Clinical Implementation of Evidence
The cross‐national differences in automobile driving precautions stated in psychotropic drug package inserts primarily reflect regulatory policies and insufficient evaluation method standardization until recent years, rather than intrinsic ethnic differences. In January 2025, the Ministry of Health, Labour and Welfare (MHLW) of Japan issued the Criteria for Determining the Effects of Psychotropic Drugs on Motor Vehicle Driving Performance. These criteria were published as an appendix to an earlier guideline for evaluating these effects published in December 2022. These guidelines and criteria, developed by the authors, provide methods for evaluating the effects of psychotropic drugs. However, these are not intended to assess the fitness of an individual patient to drive. The MHLW guideline and criteria recommend a tiered approach for assessing clinically meaningful driving impairment. Adverse events affecting alertness, such as drowsiness, caused by psychotropic drugs on driving performance are more frequent during the initial treatment stages and dose escalation. Therefore, evaluating the effects of psychotropic drugs on driving performance requires careful consideration of the persistence of clinically meaningful impairment. Additionally, understanding the magnitude and duration of such effects is crucial for selecting appropriate treatments and offering effective guidance to patients. The MHLW criteria categorize the effects of psychotropic drugs on driving performance into four levels based on their magnitude and duration. Furthermore, the MHLW criteria could help to determine which clinical trials are necessary to evaluate the persistence of clinically meaningful impairment. Namely, the MHLW criteria could be used to structure the substantial evidence needed for evaluating the effects on driving performance for approval applications and clinical implementation.
- Open Access
- 24 January 2026
- Published by Elsevier in Transportation Research Interdisciplinary Perspectives
- Vol. 36
Machine-learning evaluation of driving performance in schizophrenia: A pilot study with short-duration driving simulator tasks
- 24 January 2026
- Published by Elsevier in Transportation Research Interdisciplinary Perspectives
- Vol. 36
Open AccessMachine-learning evaluation of driving performance in schizophrenia: A pilot study with short-duration driving simulator tasks
- Open Access
- 23 August 2025
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 79 (11) , 757-764
Driving performance in the morning after bedtime vornorexant administration: A randomized clinical trial using a driving simulator
Aim: Sedative hypnotics can impair driving performance to a degree comparable to blood alcohol concentrations of 0.05%–0.08%. This study aimed to evaluate the residual effect of vornorexant, a novel orexin receptor antagonist, on next morning driving performance relative to a predefined clinically meaningful threshold. Methods: Participants received 10 and 20 mg of vornorexant and placebo for eight consecutive nights and zopiclone on Days 1 and 8 in a four‐way crossover and double‐blind manner. Driving performance at 9‐h post‐dose was assessed measuring the standard deviation of the lateral position (SDLP) on Days 2 and 9 (days after single and repeated administration) using a validated driving simulator. Pharmacokinetics were also evaluated. Results: Sixty‐one participants were randomized and 55 completed the study. The mean of drug‐placebo changes in SDLP (ΔSDLP) following vornorexant 10 and 20 mg were 0.767 and 2.132 cm on Day 2, and −0.422 and −0.040 cm on Day 9, respectively, whereas approximately 6 cm in zopiclone. All the upper bounds of the 90% confidence intervals of these changes were below the predefined clinically significant threshold. Symmetry analysis found no differences in the proportion of participants with ΔSDLP exceeding the threshold in either impairing or improving from 0 cm, at vornorexant 10 mg on Days 2 and 9 and 20 mg on Day 9. Pharmacokinetic analysis showed consistent plasma concentrations of vornorexant in single and repeated dosing. Conclusions: Single and repeated administration of 10 and 20 mg vornorexant induced no clinically meaningful impairment in driving performance in healthy Japanese participants.
- 23 August 2025
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 79 (11) , 757-764
Open AccessDriving performance in the morning after bedtime vornorexant administration: A randomized clinical trial using a driving simulator
Aim: Sedative hypnotics can impair driving performance to a degree comparable to blood alcohol concentrations of 0.05%–0.08%. This study aimed to evaluate the residual effect of vornorexant, a novel orexin receptor antagonist, on next morning driving performance relative to a predefined clinically meaningful threshold. Methods: Participants received 10 and 20 mg of vornorexant and placebo for eight consecutive nights and zopiclone on Days 1 and 8 in a four‐way crossover and double‐blind manner. Driving performance at 9‐h post‐dose was assessed measuring the standard deviation of the lateral position (SDLP) on Days 2 and 9 (days after single and repeated administration) using a validated driving simulator. Pharmacokinetics were also evaluated. Results: Sixty‐one participants were randomized and 55 completed the study. The mean of drug‐placebo changes in SDLP (ΔSDLP) following vornorexant 10 and 20 mg were 0.767 and 2.132 cm on Day 2, and −0.422 and −0.040 cm on Day 9, respectively, whereas approximately 6 cm in zopiclone. All the upper bounds of the 90% confidence intervals of these changes were below the predefined clinically significant threshold. Symmetry analysis found no differences in the proportion of participants with ΔSDLP exceeding the threshold in either impairing or improving from 0 cm, at vornorexant 10 mg on Days 2 and 9 and 20 mg on Day 9. Pharmacokinetic analysis showed consistent plasma concentrations of vornorexant in single and repeated dosing. Conclusions: Single and repeated administration of 10 and 20 mg vornorexant induced no clinically meaningful impairment in driving performance in healthy Japanese participants.
- Open Access
- 1 July 2025
- Published by Taylor & Francis in Nature and Science of Sleep
- Vol. ume 17, 1709-1726
Gut Microbiome Composition Changes During Insomnia Treatment with Lemborexant
Purpose: Insomnia is a common disorder worldwide. Growing evidence has revealed that the microbiota–gut–brain axis contributes to the regulation of sleep continuity and duration, both directly and indirectly. Although lemborexant is effective in treating insomnia, its effect on the gut microbiota remains unclear. Here, we investigated the relationship between the gut microbiota and hypnotic use in insomnia. Participants and Methods: We enrolled 29 adults with insomnia and performed sleep electroencephalography and stool analyses at baseline and after 4 and 12 weeks of open-label lemborexant treatment. Changes in gut microbiota were analyzed using 16S rRNA sequencing and metabolite analysis was performed to assess short-chain fatty acids (SCFAs). Results: Beta diversity (Jaccard dissimilarity) and Firmicutes/Bacteroidetes ratio significantly increased after administration of lemborexant for 12 weeks (p < 0.05). Seven genera were significantly different (p < 0.05). Among these, Tannerellaceae Parabacteroides decreased significantly after 12 weeks of lemborexant treatment (p = 0.013), even after correcting for false discovery rates. Akkermansia was strongly negatively correlated with sleep efficiency (r = − 0.754, p = 0.0003). Allisonella showed opposite correlations with latency to persistent sleep and sleep efficiency after 12 weeks of lemborexant treatment (r = 0.523, p = 0.018, r = − 0.516, p = 0.020, respectively). There were no significant differences in SCFAs during the treatment period. Conclusion: Our findings suggest that prolonged lemborexant treatment in individuals with insomnia may induce notable shifts in gut microbiota composition, including a significant reduction in Parabacteroides underscoring the potential interaction between hypnotic use and gut microbial balance.
- 1 July 2025
- Published by Taylor & Francis in Nature and Science of Sleep
- Vol. ume 17, 1709-1726
Open AccessGut Microbiome Composition Changes During Insomnia Treatment with Lemborexant
Purpose: Insomnia is a common disorder worldwide. Growing evidence has revealed that the microbiota–gut–brain axis contributes to the regulation of sleep continuity and duration, both directly and indirectly. Although lemborexant is effective in treating insomnia, its effect on the gut microbiota remains unclear. Here, we investigated the relationship between the gut microbiota and hypnotic use in insomnia. Participants and Methods: We enrolled 29 adults with insomnia and performed sleep electroencephalography and stool analyses at baseline and after 4 and 12 weeks of open-label lemborexant treatment. Changes in gut microbiota were analyzed using 16S rRNA sequencing and metabolite analysis was performed to assess short-chain fatty acids (SCFAs). Results: Beta diversity (Jaccard dissimilarity) and Firmicutes/Bacteroidetes ratio significantly increased after administration of lemborexant for 12 weeks (p < 0.05). Seven genera were significantly different (p < 0.05). Among these, Tannerellaceae Parabacteroides decreased significantly after 12 weeks of lemborexant treatment (p = 0.013), even after correcting for false discovery rates. Akkermansia was strongly negatively correlated with sleep efficiency (r = − 0.754, p = 0.0003). Allisonella showed opposite correlations with latency to persistent sleep and sleep efficiency after 12 weeks of lemborexant treatment (r = 0.523, p = 0.018, r = − 0.516, p = 0.020, respectively). There were no significant differences in SCFAs during the treatment period. Conclusion: Our findings suggest that prolonged lemborexant treatment in individuals with insomnia may induce notable shifts in gut microbiota composition, including a significant reduction in Parabacteroides underscoring the potential interaction between hypnotic use and gut microbial balance.
- Open Access
- 24 June 2025
- Published by Springer Nature in Psychopharmacology
- Vol. 243 (1) , 133-143
Effect of lemborexant on sleep-wake state discrepancy in participants with insomnia disorder
Rationale: The efficacy of hypnotic drugs for sleep-wake state discrepancy remains unclear. Objective: This study evaluated the efficacy of lemborexant in improving sleep-wake state discrepancy in insomnia disorder and its associations with sleep quality and daytime functioning. Methods: Twenty-nine participants diagnosed with insomnia disorder were treated with lemborexant for 12 weeks. Objective sleep parameters were measured using a home electroencephalography device, and subjective parameters were obtained from electronic sleep diaries. Sleep-wake state discrepancy indices, including discrepancies of sleep onset latency (disSOL), wake after sleep onset (disWASO), total sleep time (disTST), and sleep efficiency (disSE), were calculated as objective minus subjective sleep parameters. The Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS) were used to assess sleep quality and daytime sleepiness. Linear mixed-effects models were used for data analysis. Results: Both subjective and objective sleep parameters were improved at 12 weeks after lemborexant administration. The disTST decreased significantly at 4 and 12 weeks. The disSOL increased and disSE decreased significantly by 12 weeks. Participants with defined sleep-wake state discrepancy (disTST > 0 min) showed greater decreases in these indices, whereas minimal changes were observed in those without. The disWASO did not change significantly among baseline and 4 and 12 weeks. The improvement in disTST demonstrated a significant association with the reduction of ESS scores ( p = 0.008), whereas there was no substantial effect on PSQI scores. Conclusions: The present findings suggest that lemborexant treatment reduces sleep-wake state discrepancy, which may be associated with improved daytime functioning in patients with insomnia disorder.
- 24 June 2025
- Published by Springer Nature in Psychopharmacology
- Vol. 243 (1) , 133-143
Open AccessEffect of lemborexant on sleep-wake state discrepancy in participants with insomnia disorder
Rationale: The efficacy of hypnotic drugs for sleep-wake state discrepancy remains unclear. Objective: This study evaluated the efficacy of lemborexant in improving sleep-wake state discrepancy in insomnia disorder and its associations with sleep quality and daytime functioning. Methods: Twenty-nine participants diagnosed with insomnia disorder were treated with lemborexant for 12 weeks. Objective sleep parameters were measured using a home electroencephalography device, and subjective parameters were obtained from electronic sleep diaries. Sleep-wake state discrepancy indices, including discrepancies of sleep onset latency (disSOL), wake after sleep onset (disWASO), total sleep time (disTST), and sleep efficiency (disSE), were calculated as objective minus subjective sleep parameters. The Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS) were used to assess sleep quality and daytime sleepiness. Linear mixed-effects models were used for data analysis. Results: Both subjective and objective sleep parameters were improved at 12 weeks after lemborexant administration. The disTST decreased significantly at 4 and 12 weeks. The disSOL increased and disSE decreased significantly by 12 weeks. Participants with defined sleep-wake state discrepancy (disTST > 0 min) showed greater decreases in these indices, whereas minimal changes were observed in those without. The disWASO did not change significantly among baseline and 4 and 12 weeks. The improvement in disTST demonstrated a significant association with the reduction of ESS scores ( p = 0.008), whereas there was no substantial effect on PSQI scores. Conclusions: The present findings suggest that lemborexant treatment reduces sleep-wake state discrepancy, which may be associated with improved daytime functioning in patients with insomnia disorder.
- Open Access
- 6 April 2025
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 138, 111349
Impact of antipsychotics on prolactin levels in youth with psychiatric disorders: A cross-sectional study
- 6 April 2025
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 138, 111349
Open AccessImpact of antipsychotics on prolactin levels in youth with psychiatric disorders: A cross-sectional study
- Open Access
- 21 January 2025
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 79 (3) , 117-124
Second‐generation antipsychotic‐induced dystonia: Analysis using the Japanese Adverse Drug Event Report (JADER) database
Aim: This study aimed to explore the comparative risks for dystonia among different second‐generation antipsychotics (SGAs), the influence of sex, and the relationship between the time‐to‐onset of dystonia and its outcomes.Methods: We analyzed data from the Japanese Adverse Drug Event Report database from April 2004 to November 2023. Cases involving oral SGAs, excluding clozapine, were extracted. We used the odds ratios to assess the reporting proportions among SGAs and sex, analyzed the median time‐to‐onset and interquartile ranges (IQRs), and conducted a receiver operating characteristic (ROC) curve analysis to investigate the time‐to‐onset of dystonia and its relationship to outcomes.Results: We extracted 9837 cases involving oral SGAs. Lurasidone was associated with a significantly higher proportion of dystonia reports than risperidone, aripiprazole, quetiapine, and olanzapine. The reporting proportion of dystonia associated with aripiprazole was lower than that of paliperidone and risperidone, but higher than that of quetiapine and olanzapine. Female sex was significantly associated with a higher reporting proportion of dystonia compared with males. Among the 148 cases of oral SGA‐induced dystonia, the median time‐to‐onset was 125 days (IQR, 19.75–453.25 days). Divided into the three outcome groups (recovered, improved, and unrecovered/residual), those with better outcomes had a shorter time‐to‐onset than those with poorer outcomes. ROC curve analysis suggested a threshold of 91.5 days for discriminating outcomes, with a sensitivity of 71.7% and specificity of 69.9%.Conclusions: The risks of dystonia may vary among SGAs and between sexes. SGA‐induced dystonia often manifests in the tardive form.
- 21 January 2025
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 79 (3) , 117-124
Open AccessSecond‐generation antipsychotic‐induced dystonia: Analysis using the Japanese Adverse Drug Event Report (JADER) database
Aim: This study aimed to explore the comparative risks for dystonia among different second‐generation antipsychotics (SGAs), the influence of sex, and the relationship between the time‐to‐onset of dystonia and its outcomes.Methods: We analyzed data from the Japanese Adverse Drug Event Report database from April 2004 to November 2023. Cases involving oral SGAs, excluding clozapine, were extracted. We used the odds ratios to assess the reporting proportions among SGAs and sex, analyzed the median time‐to‐onset and interquartile ranges (IQRs), and conducted a receiver operating characteristic (ROC) curve analysis to investigate the time‐to‐onset of dystonia and its relationship to outcomes.Results: We extracted 9837 cases involving oral SGAs. Lurasidone was associated with a significantly higher proportion of dystonia reports than risperidone, aripiprazole, quetiapine, and olanzapine. The reporting proportion of dystonia associated with aripiprazole was lower than that of paliperidone and risperidone, but higher than that of quetiapine and olanzapine. Female sex was significantly associated with a higher reporting proportion of dystonia compared with males. Among the 148 cases of oral SGA‐induced dystonia, the median time‐to‐onset was 125 days (IQR, 19.75–453.25 days). Divided into the three outcome groups (recovered, improved, and unrecovered/residual), those with better outcomes had a shorter time‐to‐onset than those with poorer outcomes. ROC curve analysis suggested a threshold of 91.5 days for discriminating outcomes, with a sensitivity of 71.7% and specificity of 69.9%.Conclusions: The risks of dystonia may vary among SGAs and between sexes. SGA‐induced dystonia often manifests in the tardive form.
- Open Access
- 20 January 2025
- Published by Elsevier in Sleep Medicine
- Vol. 127, 166-169
Association of sleep-wake state discrepancy and depressive symptoms with restorative sleep in patients with depression
- 20 January 2025
- Published by Elsevier in Sleep Medicine
- Vol. 127, 166-169
Open AccessAssociation of sleep-wake state discrepancy and depressive symptoms with restorative sleep in patients with depression